Just after 10 AM central -Monday:"(NASDAQ: ONXX) today announced that it will hold a conference call to discuss data presented at an ASCO plenary session from the DECISION study, a Phase 3 trial investigating the use of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer. The call will feature the principal investigator, Marcia Brose, M.D., Ph.D., Assistant Professor in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, and will include members of Onyx's management. "
The abstract of this trial will be posted on the ASCO site at 7:30am ET tomorrow (Sunday). The prominent placement of this presentation in the schedule and the fact that it has not been released beforehand (latebreaking data?) seems encouraging to me.
Nidan, it depends on if any new (and exiting) data will be presented AND the direction on the market. I do not expect more than 4 points at the best...IMO. I also think that we're now in the leg up that should bring us to intermediate top at $110- probably in 1-1.5 months. After that- will talk!